On January 14, 2026, LENZ Therapeutics launched the “Make it VIZZable” consumer campaign featuring Sarah Jessica Parker as brand ambassador for VIZZ™ (aceclidine ophthalmic solution) 1.44%. This once-daily eye drop restores near vision for up to 10 hours, offering an alternative to reading glasses. Parker, one of an estimated 128 million Americans affected by age-related blurry near vision, shared how VIZZ eliminated her need for constant glasses and improved everyday activities such as checking her phone, applying makeup and reading scripts. LENZ CEO Eef Schimmelpennink emphasized that Parker’s relatable experience will drive awareness of a new, non-invasive option for presbyopia, with campaign content rolling out across digital platforms and in-office materials at eye care practices nationwide.

VIZZ’s efficacy stems from its pupil-selective miotic mechanism, contracting the iris sphincter muscle to create a pinhole effect and extend depth of focus without inducing a myopic shift. In the CLARITY Phase 3 trial, 93% of participants achieved near vision of 20/40 or better within 30 minutes of instillation, with benefits lasting up to 10 hours. The drop is preservative-free and delivered in single-dose vials. Safety data showed that the most common adverse reactions were instillation site irritation (20%), dim vision (16%) and headache (13%), with the majority of events rated mild and transient. LENZ continues to educate eye care professionals on best practices for prescribing and patient counseling.

Seven research firms currently cover LENZ Therapeutics, assigning a consensus recommendation of “Moderate Buy” and an average 12-month target price of $56.40. Among these, one analyst rates the company a sell, one a hold and five a buy. In the quarter ended September 30, 2025, LENZ reported revenue of $12.5 million, surpassing consensus estimates of $4.64 million, and delivered EPS of (0.59), beating the forecast by $0.08. Institutional ownership stands at approximately 54%, with recent insider transactions including a 10,000-share sale by Shawn Olsson and a 10,500-share purchase by director James W. Mccollum. Analysts project full-year EPS of (2.18), reflecting continued investment in commercialization efforts.